Juvenile rheumatoid arthritis (JRA) is a general term for arthritis in children. It is characterized by joint inflammation, swelling, and pain. There are different subtypes classified by the number and pattern of involved joints. Treatment has shifted to more aggressive early treatment with medications to prevent long-term joint damage, and may include NSAIDs, disease-modifying antirheumatic drugs like methotrexate, biologic medications, and corticosteroids depending on the subtype and severity of symptoms. JRA can cause long-term disabilities but early treatment aims to improve prognosis and prevent complications.
17. Before the 1990s … Pyramid Approach Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
Hinweis der Redaktion
ADD TRANSITION: UNEMPLOYMENT
VIOXX: 2 to 11 years of age: 0.6 mg/kg to a maximum of 25 mg once daily. Pts < 40 kg, recommended to use 12.5 mg/5 mL suspension. 12 to 17 yrs, 25 mg once daily. Maximum daily dose 25 mg. Adverse Events: Upper/abdominal pain, headache, upper respiratory tract infection, pyrexia, skin/subcutaneous disorders, insomnia, dizziness, elevated hepatic enzymes, edema, pseudoporphyria.
MTX: ADD AE PROFILE LAST BULLET NEEDS TO BE MODIFIED
![Definition - JRA ,[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)